论文部分内容阅读
人白细胞介素-2(IL-2),在抗肿瘤,免疫缺陷病和自身免疫病的诊治中具有肯定的疗效和光辉的前景,以往IL-2的制备系从人外周血单核细胞或免疫器官如:扁桃体、脾脏等淋巴细胞培养诱生,因其产量小、效价低而不能满足科研和临床的需要.根据“863”和“7.5”攻关计划,1988年我国成功的组建了IL-2工程菌并筛选出高效表达菌株以来,经过2年多的不懈努力,已形成了稳定的生产工艺,现已达到中试水平.军事医学科学院生物工程研究所申
Human Interleukin-2 (IL-2) has a promising therapeutic and bright prospect in the diagnosis and treatment of anti-tumor, immunodeficiency and autoimmune diseases. In the past, IL-2 was produced from human peripheral blood mononuclear cells or Immune organs such as: tonsil, spleen and other lymphocyte culture induced, because of its low yield, low titer can not meet the needs of scientific research and clinical.According to “863” and “7.5” research project, in 1988 China successfully established the IL -2 engineered bacteria and screened the highly expressed strains, after more than two years of unremitting efforts, has formed a stable production process, has now reached the pilot level. Institute of Biomedical Engineering, Academy of Military Medical Sciences